Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 6/20 | 0.69 |
| ▸ | ESR1 | P03372 | 1/20 | 0.69 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.53 |
| ▸ | NCOR2 | Q9Y618 | 5/20 | 0.53 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | PCLAF | Q15004 | 1/20 | 0.50 |
| ▸ | CDK2 | P24941 | 1/20 | 0.48 |
| ▸ | CDK9 | P50750 | 1/20 | 0.48 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.48 |
| ▸ | STAT3 | P40763 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 3/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.47 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21957069 | 1.00 | CRBN (0.69) | CRBNESR1HDAC1HDAC3HDAC2 | |
| SCHEMBL21957071 | 1.00 | CRBN (0.69) | CRBNESR1HDAC1HDAC3HDAC2 | |
| SCHEMBL21956350 | 1.00 | CRBN (0.69) | CRBNESR1HDAC1HDAC3HDAC2 | |
| SCHEMBL21956349 | 1.00 | CRBN (0.69) | CRBNESR1HDAC1HDAC3HDAC2 | |
| SCHEMBL21956803 | 1.00 | CRBN (0.69) | CRBNESR1HDAC1HDAC3HDAC2 | |
| SCHEMBL21956665 | 0.97 | CRBN (0.71) | CRBNESR1HDAC1HDAC3HDAC2 | |
| SCHEMBL21956662 | 0.97 | CRBN (0.71) | CRBNESR1HDAC1HDAC3HDAC2 | |
| SCHEMBL21956623 | 0.95 | CRBN (0.72) | CRBNESR1HDAC1HDAC3HDAC2 | |
| SCHEMBL21956626 | 0.95 | CRBN (0.72) | CRBNESR1HDAC1HDAC3HDAC2 | |
| SCHEMBL28406570 | 0.94 | CRBN (0.63) | CRBNESR1HDAC1HDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113164409-B | Compounds having estrogen receptor alpha degrading activity and uses thereof | 冰洲石生物科技公司 | 2023-07-18 | — | — | CN | claimed |
| EP-3675839-B1 | NOVEL COMPOUNDS HAVING ESTROGEN RECEPTOR ALPHA DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC (US) | 2023-03-01 | — | — | EP | claimed |
| CN-113164409-A | Novel compounds having estrogen receptor alpha-degrading activity and uses thereof | 冰洲石生物科技公司 | 2021-07-23 | — | — | CN | claimed |
| US-10696659-B2 | Compounds having estrogen receptor alpha degradation activity and uses thereof | ACCUTAR BIOTECHNOLOGY INC. (US) | 2020-06-30 | — | — | US | claimed |
| US-20200157078-A1 | NOVEL COMPOUNDS HAVING ESTROGEN RECEPTOR ALPHA DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2020-05-21 | — | — | US | claimed |
| CN-117050002-A | Novel compounds having estrogen receptor alpha degrading activity and uses thereof | 冰洲石生物科技公司 | 2023-11-14 | — | — | CN | disclosed |
| CN-113164409-B | Compounds having estrogen receptor alpha degrading activity and uses thereof | 冰洲石生物科技公司 | 2023-07-18 | — | — | CN | disclosed |
| CN-116234803-A | Combinations of estrogen receptor degrading agents and cyclin-dependent kinase inhibitors for the treatment of cancer | 冰洲石生物科技公司 | 2023-06-06 | — | — | CN | disclosed |
| US-11642342-B2 | Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer | Accutar Biotechnology (US) | 2023-05-09 | — | — | US | disclosed |
| US-11642342-B2 | Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer | Accutar Biotechnology (US) | 2023-05-09 | — | — | US | disclosed |
| US-11642342-B2 | Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer | Accutar Biotechnology (US) | 2023-05-09 | — | — | US | disclosed |
| EP-3675839-B1 | NOVEL COMPOUNDS HAVING ESTROGEN RECEPTOR ALPHA DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC (US) | 2023-03-01 | — | — | EP | disclosed |
| WO-2021133886-A1 | COMBINATIONS OF ESTROGEN RECEPTOR DEGRADERS AND CYCLIN-DEPENDENT KINASE INHIBITORS FOR TREATING CANCER | Accutar Biotechnology (US) | 2021-07-01 | — | — | WO | disclosed |
| US-20200299264-A1 | COMPOUNDS HAVING ESTROGEN RECEPTOR ALPHA DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2020-09-24 | — | — | US | disclosed |
| US-20200299264-A1 | COMPOUNDS HAVING ESTROGEN RECEPTOR ALPHA DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2020-09-24 | — | — | US | disclosed |
| EP-3675839-A1 | NOVEL COMPOUNDS HAVING ESTROGEN RECEPTOR ALPHA DEGRADATION ACTIVITY AND USES THEREOF | Accutar Biotechnology Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| US-10696659-B2 | Compounds having estrogen receptor alpha degradation activity and uses thereof | ACCUTAR BIOTECHNOLOGY INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-10696659-B2 | Compounds having estrogen receptor alpha degradation activity and uses thereof | ACCUTAR BIOTECHNOLOGY INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20200157078-A1 | NOVEL COMPOUNDS HAVING ESTROGEN RECEPTOR ALPHA DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2020-05-21 | — | — | US | disclosed |
| US-20200157078-A1 | NOVEL COMPOUNDS HAVING ESTROGEN RECEPTOR ALPHA DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157078-A1 | NOVEL COMPOUNDS HAVING ESTROGEN RECEPTOR ALPHA DEGRADATION ACTIVITY AND USES THEREOF | ESR2, ESRRG, ESR1 | CRBN 2038/4885ESR1 3/4885HDAC1 1689/4885 |
| US-20200299264-A1 | COMPOUNDS HAVING ESTROGEN RECEPTOR ALPHA DEGRADATION ACTIVITY AND USES THEREOF | ESR2, ESRRG, ESR1 | CRBN 2181/4885ESR1 3/4885HDAC1 1753/4885 |
| US-11642342-B2 | Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer | CDK3, CDK4, CDK1 | CRBN 1616/4885ESR1 9/4885HDAC1 706/4885 |
| US-10696659-B2 | Compounds having estrogen receptor alpha degradation activity and uses thereof | ESR2, ESRRG, ESR1 | CRBN 2181/4885ESR1 3/4885HDAC1 1753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.